Description
This volume aims to build a new generation of experts with a broader understanding of key topics in the Alzheimer’s disease field. Chapters guide readers through innovative approaches to the discovery of novel biomarkers in cerebrospinal fluid, innovation in blood-based biomarkers, a comprehensive overview of magnetic resonance imaging and molecular imaging approaches and their value for developing drugs for Alzheimer’s disease, cutting-edge developments in neuropathology and their relevance for Alzheimer’s disease trials, novel genomic strategies for biomarker development, and related topics including neuropsychological testing and advanced analytical methods.Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and cutting-edge, Biomarkers for Alzheimer’s Disease Drug Development aims to ensure successful results in the further study of this vital field. PART I: The need for Alzheimer’s Disease Biomarkers 1. Epidemiology of Dementia: The Burden on Society, the Challenges for Research Frank J. Wolters and M. Arfan Ikram 2. Population-based Approaches to Alzheimer’s Disease Prevention Robert Perneczky 3. Systems Biology Methods for Alzheimer’s Disease Research towards Molecular Signatures, Subtypes and Stages and Precision Medicine. Application in Cohort Studies and Trials Juan I. Castrillo, Simone Lista, Harald Hampel, and Craig W. Ritchie PART II: Innovative Approaches to Cerebrospinal Fluid Biomarker Discovery 4. CSF Lipidomics Analysis: High-Resolution Mass Spectrometry Analytical Platform Paul L. Wood and Randall L. Woltjer 5. CSF N-glycomics using MALDI MS Techniques in Alzheimer’s Disease Angelo Palmigiano, Angela Messina, Rosaria Ornella Bua, Rita Barone, Luisa Sturiale, Mario Zappia, and Domenico Garozzo 6. MicroRNA Profiling of Alzheimer’s Disease Cerebrospinal Fluid Johannes Denk and Holger Jahn Part III: Novel Blood-based Biomarkers 7. Validation of a Chemiluminescence Immunoassay for Measuring Amyloid- in Human Blood Plasma Jonathan Vogelgsang, Jens Wiltfang, and Hans-W. Klafki 8. Mass Spectrometry-based Metabolomic Multiplatform for Alzheimer’s Disease Research Ral Gonzlez-Domnguez, lvaro Gonzlez-Domnguez, Ana Sayago, and ngeles Fernndez-Recamales 9. Blood-based Biomarker Screening with Agnostic Biological Definitions for an Accurate Diagnosis within the Dimensional Spectrum of Neurodegenerative Diseases Filippo Baldacci, Simone Lista, Sid E. O’Bryant, Roberto Ceravolo, Nicola Toschi, and Harald Hampel, Part IV: Magnetic Resonance Imaging Methods 10. Functional Magnetic Resonance Imaging in Alzheimer’ Disease Drug Development Stefan Holiga, Ahmed Abdulkadir, Stefan Klppel, and Juergen Dukart 11. Neuroimaging Methods for MRI Analysis in CSF Biomarkers Studies Carles Falcon, Grgory Operto, Jos Luis Molinuevo, and Juan Domingo Gispert 12. Hybrid PET-MRI in Alzheimer’s Disease Research Ismini C. Mainta, Maria I. Vargas , Sara Trombella, Giovanni B. Frisoni, Paul G. Unschuld, Valentina Garibotto Part V: Molecular Imaging Approaches 13. Amyloid PET Imaging: Standardization and Integration with Other Alzheimer Disease Biomarkers Silvia Morbelli and Matteo Bauckneht 14. The use of 18F-FDG PET in the Diagnostic Workup of Alzheimer’s Dementia Marion M. Ortner 15. Quantification of Tau Load in Alzheimer’s Disease Clinical Trials Using Positron Emission Tomography Tessa Timmers, Bart N.M. van Berckel, Adriaan Lammertsma, and Rik Ossenkoppele 16. Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach Elena Rodriguez-Vieitez and Agneta Nordberg Part VI: Neuropathology 17. Unbiased Lipidomics and Metabolomics of Human Brain Samples Giuseppe Astarita, Matteo Stocchero, and Giuseppe Paglia 18. Neuropathological Assessment as an Endpoint in Clinical Trial Design Steve Gentleman and Alan King Lun Liu Part VII Genomic Methods 19. Analysis of micro-RNA Expression by qPCR on a Microfluidics Platform for Alzheimer’s Disease Biomarker Discovery Petros Takousis 20. Telomere length shortening in Alzheimer’s disease – procedures for a causal investigation using single nucleotide polymorphisms in a Mendelian Randomization study Yiqiang Zhan, Sara Hgg 21. Quantifying miRNA Deregulation in Alzheimer’s Disease Ana L. Cardoso and Joana R. Guedes Part VIII: Preclinical Research 22. Imaging of Microglial Activation in Alzheimer’s Disease by [11C]PBR28 PET Cornelius K. Donat, Nazanin Mirzaei, Sac-Pharm Tang, Paul Edison, and Magdalena Sastre 23. In Vivo Two-photon Calcium Imaging of Hippocampal Neurons in Alzheimer Mouse Models Marc Aurel Busche Part IX: Related concepts: Cognitive Testing and Advanced Analytics 24. Cognitive Assessment in Alzheimer’s Disease Clinical Trials Geraint Price 25. Data Mining and Machine Learning Methods for Dementia Research Rui Li
